Wegovy and teeth pain: what patients are noticing and why

What the pharmacological evidence actually shows about semaglutide and the mouth

The clinical trials that led to Wegovy's UK licence (principally the STEP 1 study, which was published in the New England Journal of Medicine and followed 1,961 adults over 68 weeks) recorded adverse events systematically, but dental or oral pain was not a primary or prominently reported finding. Post-marketing pharmacovigilance data collected by regulators since the medicine's wider rollout has captured a broader picture of what patients actually experience in real-world conditions, and oral complaints appear in that data, though causality is difficult to establish for something as multifactorial as tooth health.

The NHS medicines page for semaglutide lists the known side-effect profile, which is led by gastrointestinal symptoms: nausea, vomiting, reflux and constipation are the most commonly reported. These are relevant to the teeth question precisely because the mouth is the first part of the gastrointestinal tract. When stomach acid reaches the mouth repeatedly (through reflux or vomiting during the early weeks of treatment) it softens and erodes enamel. Enamel erosion exposes the dentine underneath, and dentine is sensitive. That sensitivity is what many people describe as tooth pain.

There is also early-stage scientific interest in whether GLP-1 receptors, which semaglutide activates, are expressed in salivary glands, and our dedicated page on semaglutide and teeth covers what this emerging research may mean for patients in practical terms. Saliva is a key protector of oral health: it buffers acids, remineralises enamel and rinses the mouth. If GLP-1 activity influences salivary flow, that would be a direct mechanism. Research is ongoing; no definitive clinical guidance has been issued on this point, so it remains a hypothesis worth watching rather than an established cause.

How dry mouth, reduced eating and changed hydration contribute to tooth sensitivity on Wegovy

Dry mouth (clinically, xerostomia) is reported by a meaningful proportion of people on GLP-1 medicines. It can result from reduced fluid intake (Wegovy's appetite suppression often extends to drinks as well as food), from nausea-related aversion to certain liquids, or from the early GI disturbance that settles as the dose increases. Without adequate saliva, the mouth's natural defence against acid and bacteria weakens, and sensitivity or soreness can follow within weeks.

Eating patterns shift substantially on Wegovy. Smaller, less frequent meals might sound straightforward, but the practical implications for the mouth are real. People chew less. Some switch to softer, more processed foods to make eating easier when appetite is low. Others sip acidic drinks (squash, sparkling water, fruit juice) between meals in an attempt to stay hydrated. Each of these can contribute to enamel wear or gum irritation that was not present before treatment started. If you have noticed that certain foods or temperatures now cause a twinge that was not there before, this is worth logging and discussing with your dentist.

There is a useful practical point here about timing. Patients who start treatment around a bank holiday or over a Christmas break sometimes find their dental routine slips at exactly the point their GI side effects are at their peak. Keeping up with twice-daily brushing (with a soft brush, not straight after any acid exposure) and staying hydrated are simple measures that matter more, not less, during the early weeks of treatment. For a broader picture of how Wegovy affects skin and other tissues beyond the gut, the page on skin discomfort on Wegovy covers similar secondary mechanisms.

When teeth pain during Wegovy treatment needs professional attention

Mild transient soreness that coincides with nausea in the first few weeks of treatment, then fades as the GI effects settle, is consistent with the pattern of acid-related enamel sensitivity and does not on its own signal a problem with the medicine. Telling your dentist you have recently started a GLP-1 medicine is still wise, they can check for early enamel changes and give personalised advice on remineralising toothpaste or mouthwash.

Symptoms that deserve more urgent attention are: pain that is worsening rather than settling; gum bleeding, recession or swelling; jaw pain or joint discomfort not obviously linked to clenching; or a toothache that a dentist had already been monitoring that has deteriorated since starting treatment. These may simply be coincidental dental problems (Wegovy does not prevent ordinary tooth decay) but they need assessment rather than watchful waiting.

If you are experiencing significant reflux or repeated vomiting as side effects, speak to your prescriber. Dose titration is managed by a prescriber for exactly this reason: managing GI tolerance is a clinical task, not something to work out by trial and error. The guide to gas and abdominal discomfort on Wegovy covers the GI side-effect picture in more detail, and the companion page on Wegovy and dental health goes deeper on enamel protection strategies.

Reporting any suspected side effect, including oral symptoms you believe are linked to Wegovy, can be done through the MHRA's Yellow Card scheme. That data actively shapes how regulators update prescribing guidance, so it is worth submitting even if you are unsure whether the symptoms are related.

If you are considering starting Wegovy and want to understand how our prescribers approach the full safety picture before treatment begins, our semaglutide overview sets out the clinical background, and the Wegovy treatment page covers what to expect at each stage. When you are ready, you can start your free consultation with our GPhC-registered prescribers, who review every application personally before any treatment is issued.